Who are Tamoxifen and GnRH analogue's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tamoxifen-and-gnrh-analogue.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tamoxifen and GnRH analogue — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamoxifen and GnRH analogue (Tamoxifen and GnRH analogue) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue. Area: Oncology.

phase 3 Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue Estrogen receptor and GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tamoxifen and GnRH analogue (Tamoxifen and GnRH analogue) — GBG Forschungs GmbH. Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's proliferative effects on breast cancer cells, while GnRH analogue works by downregulating GnRH receptors in the pituitary gland, leading to decreased gonadotropin secretion and subsequently reduced estrogen production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamoxifen and GnRH analogue TARGET	Tamoxifen and GnRH analogue	GBG Forschungs GmbH	phase 3	Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue	Estrogen receptor and GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue class)

GBG Forschungs GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tamoxifen and GnRH analogue — Competitive Intelligence Brief. https://druglandscape.com/ci/tamoxifen-and-gnrh-analogue. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab